EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Nurix Therapeutics's Enterprise Value is $539.96 Mil.
Nurix Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Feb. 2024 was $-83.87 Mil. Therefore, Nurix Therapeutics's EV-to-FCF for today is -6.44.
The historical rank and industry rank for Nurix Therapeutics's EV-to-FCF or its related term are showing as below:
NRIX'
s EV-to-FCF Range Over the Past 10 Years
Min: -325.62 Med: -2.55 Max: 31.03
Current: -6.44
During the past 6 years, the highest EV-to-FCF of Nurix Therapeutics was 31.03. The lowest was -325.62. And the median was -2.55.
NRIX's EV-to-FCF is ranked worse than 100% of 390
companies
in the Biotechnology industry
Industry Median: 4.475
vs NRIX: -6.44
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Nurix Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Nurix Therapeutics's EV-to-FCF
For the Biotechnology subindustry, Nurix Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nurix Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nurix Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Nurix Therapeutics's EV-to-FCF falls into.
Nurix Therapeutics's current Enterprise Value is $539.96 Mil.
Nurix Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-83.87 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Nurix Therapeutics's PE Ratio for today is calculated as:
Nurix Therapeutics's share price for today is $12.36.
Nurix Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.660.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Nurix Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Nurix Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Nurix Therapeutics (Nurix Therapeutics) Business Description
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NRIX has been successfully added to your 